The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 12, 2019
Filed:
Sep. 05, 2017
Applicants:
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);
Board of Trustees of the University of Illinois, Urbana, IL (US);
Inventors:
Eduardo M. Sotomayor, Tampa, FL (US);
Joel A. Bergman, Chicago, IL (US);
Alan P. Kozikowski, Chicago, IL (US);
Alejandro V. Villagra, Tampa, FL (US);
Karrune V. Woan, Gainesville, FL (US);
Assignees:
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);
Board of Trustees of The University of Illinois, Urbana, IL (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/17 (2006.01); C07C 275/34 (2006.01); C07D 213/75 (2006.01); C07D 231/56 (2006.01); C07D 233/26 (2006.01); C07D 233/74 (2006.01); C07D 233/78 (2006.01); C07D 239/42 (2006.01); C07D 261/14 (2006.01); C07D 209/14 (2006.01); C07D 295/13 (2006.01); C07C 275/28 (2006.01); C07C 275/40 (2006.01); A61K 31/185 (2006.01); A61K 31/4045 (2006.01); A61K 31/416 (2006.01); A61K 31/42 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 31/505 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07C 275/34 (2013.01); A61K 31/17 (2013.01); A61K 31/185 (2013.01); A61K 31/4045 (2013.01); A61K 31/416 (2013.01); A61K 31/42 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/505 (2013.01); A61K 45/06 (2013.01); C07C 275/28 (2013.01); C07C 275/40 (2013.01); C07D 209/14 (2013.01); C07D 213/75 (2013.01); C07D 231/56 (2013.01); C07D 233/26 (2013.01); C07D 233/74 (2013.01); C07D 233/78 (2013.01); C07D 239/42 (2013.01); C07D 261/14 (2013.01); C07D 295/13 (2013.01);
Abstract
Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.